Wuxi capital group's invested enterprise, Paige Biotechnology, has landed on the Hong Kong Stock Exchange

　　On May 27th, the invested company Paige Biotechnology (02565. HK) of Xicheng Venture Capital was successfully listed on the Hong Kong Stock Exchange.

　　Paige Biotechnology was founded in 2008 and is a biotechnology company dedicated to independent research and development of innovative therapies for chronic diseases, with a focus on the field of endocrine metabolism. Xi Venture Capital invested in Paige Biotechnology through Guokang Fund in 2020.

　　Paige Biotechnology has developed a research and development pipeline that covers a wide range of chronic diseases using its independently developed technology system to address unmet clinical treatment needs in the field of chronic diseases. The company has independently developed a core product and five products under research, aiming to grasp the huge market potential of common chronic diseases and metabolic diseases, including type 2 diabetes (T2DM), obesity, metabolic steatohepatitis (MASH), opioid induced constipation (OIC) and congenital hyperinsulinemia.

　　Xi Venture Capital has long been deeply involved in strategic emerging industries such as biomedicine, actively exploring and cultivating high-quality targets, linking technological innovation and industrial development with capital strength, and continuously providing high-quality resources and service empowerment for enterprises in technology research and development, market expansion, and other aspects.

About Wuxi Capital Group

Wuxi Capital Group is a state-owned venture capital institution that integrates seed, angel, entrepreneurship, equity, mergers and acquisitions, and S funds. The company has established a fund system covering the entire life cycle of enterprises, managing a total fund size of over 270 billion yuan, and providing comprehensive support to enterprises that are in line with their development stages; Focusing on strategic emerging industries such as biomedicine, integrated circuits, dual carbon energy conservation, and artificial intelligence, the management fund has invested in over 1600 companies and participated in the cultivation of more than 110 listed companies such as Longda Corporation, New Clean Energy, and Time Angel.